Gyncentrum Sp. z o.o.

Running trials

• Not yet recruiting

  A study to investigate the efficacy and safety of TRIV-573 compared with placebo in participants with moderate to severe atopic dermatitis

  2026-526485-25-00· Phase 2· Source

• Not yet recruiting

  A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

  NCT07861100· Phase 3· Source

• Not yet recruiting

  Rollover Study for Participants Who Have Completed a Previous Clinical Study with Anifrolumab (Saphnelo) and Clinically Benefited from Continued Treatment.

  2026-526419-13-00· Phase 3· Source

• Recruiting

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· Phase 3· Source

• Recruiting

  AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

  NCT07797335· Phase 3· Source

• Recruiting

  A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis

  NCT07516951· Phase 2· Source

• Recruiting

  Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)

  NCT07284602· Phase 3· Source

• Recruiting

  A study of LY4268989 in participants with Moderately to Severely Active Ulcerative Colitis (EMERALD-3)

  2025-524404-29-00· Phase 2· Source

• Enrolling by invitation

  Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD

  NCT07652294· Phase 2· Source

• Recruiting

  A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis

  NCT07470879· Phase 2· Source

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Source

• Recruiting

  A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

  NCT07483073· Phase 2· Source

• Recruiting

  A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis

  2025-521546-23-00· Phase 3· Source

• Recruiting

  LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis: A Phase 2 Study

  2025-522338-30-00· Phase 2· Source

• Active, not recruiting

  A study to investigate the efficacy and safety of TRIV-509 compared with placebo in adults with moderate to severe atopic dermatitis

  2025-522113-35-00· Phase 2· Source

• Active, not recruiting

  A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

  NCT07277660· Phase 2· Source

• Recruiting

  A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

  NCT07221188· Phase 3· Source

• Recruiting

  A first-in-human, dose finding study to evaluate the safety, tolerability and pharmacokinetics of EGL-003 in healthy volunteers followed by adults with autoimmune disease.

  2025-521658-40-00· Phase 1· Source

• Recruiting

  A Study to Evaluate the Long-term Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis

  2024-519795-11-00· Phase 2· Source

• Active, not recruiting

  Trial of Sibeprenlimab in the Treatment of Sjögren’s Disease

  2024-516295-14-00· Phase 2· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

  NCT06832618· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

  NCT07037901· Phase 2· Source

• Active, not recruiting

  Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis.

  2024-515672-12-00· Phase 3· Source

• Recruiting

  A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

  NCT07012395· Phase 2· Source

• Recruiting

  Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

  NCT06677060· Phase 3· Source

• Recruiting

  Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

  NCT06830044· Phase 3· Source

• Recruiting

  A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

  NCT06742723· Phase 3· Source

• Active, not recruiting

  Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

  NCT06676319· Phase 2· Source

• Active, not recruiting

  A study to evaluate the efficacy and safety of AMY109 in women with endometriosis

  2023-507289-14-00· Phase 2· Source

• Enrolling by invitation

  Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma

  NCT06609239· Phase 2· Source

• Active, not recruiting

  A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

  NCT06550076· Phase 3· Source

• Active, not recruiting

  A Study Evaluating APG777 in Atopic Dermatitis

  NCT06395948· Phase 2· Source

• Active, not recruiting

  Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06290934· Phase 2· Source

• Active, not recruiting

  HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation.

  NCT05636176· Phase 3· Source

• Recruiting

  A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

  NCT05287126· Phase 2· Source

• Active, not recruiting

  Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis

  NCT05588843· Phase 2· Source

• Active, not recruiting

  LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women

  NCT05303636· Phase 4· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Ulcerative colitis7 recruiting
• Atopic dermatitis (eczema)4 recruiting
• Heart failure3 recruiting
• Idiopathic pulmonary fibrosis2 recruiting
• Obesity2 recruiting
• Asthma1 recruiting
• Chronic kidney disease1 recruiting
• Crohn's disease1 recruiting
• Depression1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• High blood pressure1 recruiting
• Lupus (SLE)1 recruiting
• Multiple sclerosis1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Type 1 diabetes1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis.

  2023-507705-34-00· Phase 3· Source

• Completed

  A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis

  NCT06973291· Phase 3· Source

• Completed

  Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants with Moderate to Severe Atopic Dermatitis.

  NCT06447506· Phase 2· Source

• Completed

  A Phase 2, Double-blind, Placebo-controlled, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma

  NCT06376045· Phase 2· Source

• Completed

  A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with active mild to moderate ulcerative colitis for the induction of remission.

  NCT06176560· Phase 3· Source

• Completed

  A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma

  NCT06261957· Phase 3· Source

• Completed

  A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GSK1070806 SC injection in Adult Participants with Moderate to Severe Atopic Dermatitis

  NCT05999799· Phase 2· Source

• Completed

  A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)

  NCT05882877· Phase 3· Source

• Completed

  Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis

  NCT05916365· Phase 3· Source

• Completed

  Phase 3, 52-week Study Evaluating Rocatinlimab (AMG451)in Adolescent Subjects With Moderate-to-severe AD (ROCKET-ASTRO)

  2022-501586-50-00· Phase 3· Source

• Completed

  A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05724199· Phase 3· Source